ROCHESTER, Minn. — Mayo Clinic urologists will present studies on kidney stone incidence in surgical teams, blood clot risk and survival following bladder cancer surgery, genomic testing for metastatic prostate cancer and other research at the American Urological Association's annual meeting, May 4-8, in San Diego. Mayo Clinic experts will also be available to provide comment for reporters covering the conference. Studies to be presented and their embargo dates include:
Health care professionals, especially physicians, who work in operating rooms, are at increased risk of developing kidney stones, a Mayo Clinic study has found.
Researchers surveyed more than 3,900 health care professionals at Mayo Clinic and found that nearly
11 percent had experienced kidney stones.
"Those who worked in operating rooms reported an increased prevalence of kidney stones at 14.6 percent, while physicians who worked in operating rooms reported the highest prevalence of kidney stones at 17.4 percent," says lead author Brian Linder, M.D. a Mayo Clinic urology resident.
Researchers also gathered additional information on potential risk factors for kidney stones such as quantity of daily fluid intake, stress level, activity level, body mass index, medical conditions and family history. Physicians reported significantly less fluid intake and higher stress levels when compared to colleagues not working in an operating room.
Bladder cancer patients with a non-O blood type who undergo radical cystectomy to remove the bladder and lymph nodes are at increased risk of severe venous thromboembolism such as deep venous thrombosis and pulmonary embolus, a Mayo Clinic study has found.
"Radical cystectomy has been associated with a higher risk of venous thromboembolism than any other urologic procedure," says Jeffrey Wang, M.D. a Mayo Clinic urology resident and lead author of the study. "While numerous risk factors for severe clots have been investigated, recent data among non-surgical patients has demonstrated an association between non-O blood type and venous thromboembolism."
Dr. Wang and his team identified 2,008 patients who received a radical cystectomy at Mayo Clinic between 1980 and 2005. The team evaluated the association of blood type with venous thromboembolism, controlling for patient age, tumor and cancer stage, body-mass index, the total number of lymph nodes removed in surgery and quality of life using a standardized scale measuring the patient's daily living ability.
Urologists at Mayo Clinic have developed a model to predict individual patient outcomes following surgery for bladder cancer.
"There are many clinical observations that can help determine patient outcomes following surgery for bladder cancer beyond what is currently used," says lead author Manuel Eisenberg, M.D., a Mayo Clinic urologic oncology fellow. "However, there currently is no tool that assesses the relative importance of these variables to develop an individualized risk assessment for each patient."
Dr. Eisenberg and his team developed the survival prediction after radical cystectomy model after evaluating data on 1,776 Mayo Clinic patients who had surgery for bladder cancer between 1980 and 2008 without pre-surgical chemotherapy. The model is based on clinical and pathologic characteristics significantly associated with death following surgery for bladder cancer. Pending external validation, the data may eventually be used for patient counseling and recommendations for additional therapy and cancer surveillance.
Researchers at Mayo Clinic have validated a new genomic test to predict metastatic prostate cancer progression. The test was evaluated in a blinded study of 1,010 Mayo Clinic patients at high risk for the spread of prostate cancer.
"The test is a better predictor of disease progression when compared with traditional clinical variables and it may also help identify patients who are likely to have less aggressive cancer," says lead author Jeffrey Karnes, M.D., a Mayo Clinic urologist. Dr. Karnes says 30 to 40 percent of men who have a radical prostatectomy to treat prostate cancer are at high risk for spread of the disease.
Mayo Clinic has licensed the test to Genome Dx Biosciences, which develops and commercializes genetic-based medical tests. The company is based in San Diego and Vancouver, British Columbia.Posted by mayonewsreleases